SCHEMBL26812964

SCHEMBL26812964

O=C(O)c1cccc(S(=O)(=O)Nc2nc(Oc3ccccc3)cc(-c3ccccc3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.52
PFKFB3 Q16875 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ACLY P53396 1/20 0.48
MAPT P10636 1/20 0.48
KDM4E B2RXH2 1/20 0.47
TSHR P16473 1/20 0.47
PTK2B Q14289 1/20 0.47
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HSPD1 P10809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26811138 0.94 MAPT (0.49) AKR1C3PFKFB3KMT2AMEN1MAPK1
SCHEMBL26811129 0.89 MAPT (0.50) KMT2AMEN1MAPK1TDP1MAPT
SCHEMBL26812970 0.88 MAPT (0.49) KMT2AMEN1MAPK1TDP1ACLY
SCHEMBL26806813 0.87 MAPT (0.61) KMT2AMEN1MAPK1TDP1MAPT
SCHEMBL24310547 0.87 MAPT (0.50) KMT2AMEN1MAPK1TDP1MAPT
SCHEMBL26812958 0.85 MAPT (0.48) AKR1C3KMT2AMEN1MAPK1TDP1
SCHEMBL24310182 0.84 MAPT (0.59) KMT2AMEN1MAPK1TDP1MAPT
SCHEMBL26812980 0.84 MAPT (0.50) KMT2AMEN1MAPK1TDP1MAPT
SCHEMBL24310185 0.84 PGR (0.58) MAPK1TDP1MAPTTSHRHSPD1
SCHEMBL26810854 0.84 MCL1 (0.50) MAPK1TDP1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B AKR1C3 3005/4885PFKFB3 2800/4885KMT2A 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.